Xenetic Biosciences Reports 2025 Results; Xeris Biopharma Schedules Earnings Release

Xenetic Biosciences, Inc. (NASDAQ:XBIO) reported its financial results for the year ended December 31, 2025, showing a net loss of approximately $2.7 million as the company advanced its DNase-based immuno-oncology technology toward Phase 1 clinical development. The company ended the year with approximately $7.9 million of cash, representing an increase of approximately $1.7 million compared to the prior year-end, primarily due to net proceeds of approximately $4.0 million from an underwritten public offering completed in October 2025.

Royalty revenue from the company's sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and development expenses for the year ended December 31, 2025 decreased by approximately $0.2 million, or 7%, to $3.1 million from $3.3 million in the prior year period. Research and development costs for the year ended December 31, 2024 included a $0.7 million impairment charge that did not reoccur in 2025. This decrease was substantially offset by increased spending in connection with the company's DNase process development efforts.

General and administrative expenses for the year ended December 31, 2025 were $2.7 million, decreasing by approximately $0.7 million, or 20%, compared to the prior year. This decrease was primarily due to certain severance and benefits expensed during the year ended December 31, 2024 in connection with a separation agreement entered into during the second quarter of 2024 with the former Chief Executive Officer.

During 2025, Xenetic expanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase)-based interventions. The company progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including an ongoing pancreatic ductal adenocarcinoma (PDAC) study and a proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy.

Xenetic advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application. The company completed preclinical studies evaluating DNase I in combination with chemotherapy, immunotherapies and CAR-T approaches across both solid and hematologic cancer models. Data generated from these studies are informing ongoing translational work and manufacturing activities as the company progresses toward U.S. IND submission. The company is pursuing strategic alternatives to maximize shareholder value.

Separately, Xeris Biopharma Holdings will announce its fourth quarter and full year 2025 financial results before the U.S. market opens on March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the company's financial and operational results. Investors can pre-register for the conference call via the provided link, with a recommendation to register at least ten minutes in advance to ensure smooth participation.

Xeris currently has three commercially available products: Recorlev for the treatment of endogenous Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism.